<DOC>
	<DOCNO>NCT00950599</DOCNO>
	<brief_summary>To evaluate positive efficacy trend among dos saxagliptin ( BMS-477118 ) subject Type 2 diabetes mellitus assess change baseline HbA1c follow 12 week double-blind treatment .</brief_summary>
	<brief_title>Study Multiple Doses Saxagliptin ( BMS-477118 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Type 2 diabetes drugnaive Screening HbA1c ≥ 6.8 % ≤ 9.7 % Screening fasting random Cpeptide &gt; 0.5 ng/mL &lt; 35 year old must negative antiGAD antibody Body Mass Index &lt; 35 kg/m2 Symptoms poorly control diabetes History diabetic ketoacidosis , hyperosmolar nonketotic coma , insulin therapy within one year screen Receipt oral antihyperglycemic medication six month total since diagnosis Significant cardiovascular history</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>